Published in Lancet Oncol on September 18, 2014
A chemical probe toolbox for dissecting the cancer epigenome. Nat Rev Cancer (2017) 1.40
Proteotoxic crisis, the ubiquitin-proteasome system, and cancer therapy. BMC Biol (2014) 1.29
Multiple Myeloma: Diagnosis and Treatment. Mayo Clin Proc (2016) 1.07
Targeting the cancer epigenome for therapy. Nat Rev Genet (2016) 1.01
Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM. Blood (2016) 0.96
Epigenetic treatment of solid tumours: a review of clinical trials. Clin Epigenetics (2015) 0.96
Histone acetyltransferases and histone deacetylases in B- and T-cell development, physiology and malignancy. Genes Cancer (2015) 0.95
Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment. Blood (2015) 0.94
Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol (2016) 0.94
Myeloma today: Disease definitions and treatment advances. Am J Hematol (2016) 0.94
Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma. Haematologica (2015) 0.90
Promising therapies in multiple myeloma. Blood (2015) 0.89
Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma. Haematologica (2015) 0.89
Estimating the Costs of Therapy in Patients with Relapsed and/or Refractory Multiple Myeloma: A Model Framework. Am Health Drug Benefits (2015) 0.88
New investigational drugs with single-agent activity in multiple myeloma. Blood Cancer J (2016) 0.87
Epigenetic Therapeutics: A New Weapon in the War Against Cancer. Annu Rev Med (2016) 0.87
Phase II study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome 2009-01 trial. Haematologica (2014) 0.84
Treatment of relapsed and refractory multiple myeloma. Haematologica (2016) 0.83
Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group. Leukemia (2015) 0.83
Evolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexity. Bone Marrow Transplant (2016) 0.82
Current therapeutic strategies for multiple myeloma. Int J Clin Oncol (2015) 0.81
Next-generation multiple myeloma treatment: a pharmacoeconomic perspective. Blood (2016) 0.81
Epigenetics in diagnosis, prognostic assessment and treatment of cancer: an update. EXCLI J (2014) 0.81
Epigenetic targets for novel therapies of lung diseases. Pharmacol Ther (2014) 0.81
Role of Histone Deacetylase Inhibitors in Relapsed Refractory Multiple Myeloma: A Focus on Vorinostat and Panobinostat. Pharmacotherapy (2015) 0.81
Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma. Blood (2016) 0.80
Clinical use and applications of histone deacetylase inhibitors in multiple myeloma. Clin Pharmacol (2016) 0.78
Progress and Paradigms in Multiple Myeloma. Clin Cancer Res (2016) 0.78
Phase 1 trial of carfilzomib (PR-171) in combination with vorinostat (SAHA) in patients with relapsed or refractory B-cell lymphomas. Leuk Lymphoma (2015) 0.78
American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. Biol Blood Marrow Transplant (2015) 0.78
Recent advances in understanding multiple myeloma. F1000Res (2016) 0.78
Evidence of long-term disease control with panobinostat maintenance in patients with relapsed multiple myeloma. Haematologica (2015) 0.78
Treatment-related symptom management in patients with multiple myeloma: a review. Support Care Cancer (2015) 0.78
Panobinostat for the treatment of multiple myeloma. Lancet Oncol (2014) 0.77
Histone deacetylase inhibitor panobinostat induces calcineurin degradation in multiple myeloma. JCI Insight (2016) 0.77
Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party. Leukemia (2016) 0.77
HDAC5 controls the functions of Foxp3(+) T-regulatory and CD8(+) T cells. Int J Cancer (2016) 0.77
The next generation of novel therapies for the management of relapsed multiple myeloma. Future Oncol (2016) 0.76
DNA Methylation and Chromatin Remodeling: The Blueprint of Cancer Epigenetics. Scientifica (Cairo) (2016) 0.76
Panobinostat (Farydak): A Novel Option for the Treatment of Relapsed Or Relapsed and Refractory Multiple Myeloma. P T (2016) 0.76
An immediate transcriptional signature associated with response to the histone deacetylase inhibitor Givinostat in T acute lymphoblastic leukemia xenografts. Cell Death Dis (2016) 0.76
Panobinostat PK/PD profile in combination with bortezomib and dexamethasone in patients with relapsed and relapsed/refractory multiple myeloma. Eur J Clin Pharmacol (2015) 0.76
Rational Combinations of Targeted Agents in AML. J Clin Med (2015) 0.76
Salvage therapies in relapsed and/or refractory myeloma: what is current and what is the future? Onco Targets Ther (2016) 0.76
Pooled analysis of the reports of carfilzomib, panobinostat, and elotuzumab combinations in patients with refractory/relapsed multiple myeloma. J Hematol Oncol (2016) 0.76
Panobinostat for the treatment of multiple myeloma: the evidence to date. J Blood Med (2015) 0.76
Innovations in treatment and response evaluation in multiple myeloma. Haematologica (2016) 0.76
Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Non-small Cell Lung Cancer. Cancer Discov (2017) 0.75
The Diagnosis and Treatment of Multiple Myeloma. Dtsch Arztebl Int (2016) 0.75
Posttransplant maintenance therapy in multiple myeloma: the changing landscape. Blood Cancer J (2017) 0.75
Epigenetic therapy approaches in non-small cell lung cancer: Update and perspectives. Epigenetics (2016) 0.75
Multiple myeloma: patient outcomes in real-world practice. Br J Haematol (2016) 0.75
Evolving Paradigms in the Management of Multiple Myeloma: Novel Agents and Targeted Therapies. Rare Cancers Ther (2015) 0.75
The Danish National Multiple Myeloma Registry. Clin Epidemiol (2016) 0.75
Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma. Proc Natl Acad Sci U S A (2016) 0.75
The Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European Perspective. Adv Ther (2016) 0.75
Dinutuximab and Panobinostat. Hosp Pharm (2015) 0.75
Patterns of relapse and outcome of elderly multiple myeloma patients treated as front-line therapy with novel agents combinations. Leuk Res Rep (2015) 0.75
Minimal Residual Disease Assessment in the Context of Multiple Myeloma Treatment. Curr Hematol Malig Rep (2016) 0.75
Recent advances in multiple myeloma: a Korean perspective. Korean J Intern Med (2016) 0.75
AACR Cancer Progress Report 2015. Clin Cancer Res (2015) 0.75
PD-1/PD-L1 inhibitors in multiple myeloma: The present and the future. Oncoimmunology (2016) 0.75
A novel histone deacetylase inhibitor, CKD5, has potent anti-cancer effects in glioblastoma. Oncotarget (2016) 0.75
Update on the optimal use of bortezomib in the treatment of multiple myeloma. Cancer Manag Res (2017) 0.75
A look backward and forward in the regulatory and treatment history of multiple myeloma: Approval of novel-novel agents, new drug development, and longer patient survival. Semin Oncol (2016) 0.75
Proteasome inhibitors in cancer therapy. Nat Rev Clin Oncol (2017) 0.75
Efficacy and Safety of Panobinostat in Relapsed or/and Refractory Multiple Myeloma: Meta Analyses of Clinical Trials and Systematic Review. Sci Rep (2016) 0.75
Measles Elimination - Using Outbreaks to Identify and Close Immunity Gaps. N Engl J Med (2016) 0.75
Multiple myeloma in the marrow: pathogenesis and treatments. Ann N Y Acad Sci (2016) 0.75
In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma. Oncotarget (2015) 0.75
Clinical developments in the treatment of relapsed or relapsed and refractory multiple myeloma: impact of panobinostat, the first-in-class histone deacetylase inhibitor. Onco Targets Ther (2016) 0.75
Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer(®), alone and with bortezomib-dexamethasone in relapsed/refractory multiple myeloma: A phase IIa study. Leukemia (2017) 0.75
Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265 mutations. JCI Insight (2017) 0.75
Histone Deacetylase Inhibitors Enhance the Therapeutic Potential of Reovirus in Multiple Myeloma. Mol Cancer Ther (2016) 0.75
A clinical update on the role of carfilzomib in the treatment of relapsed or refractory multiple myeloma. Ther Adv Hematol (2016) 0.75
Cost of Treatment for Relapsed/Refractory Multiple Myeloma. Am Health Drug Benefits (2015) 0.75
Action mechanisms of histone deacetylase inhibitors in the treatment of hematological malignancies. Cancer Sci (2016) 0.75
Epigenetic strategies to reverse drug resistance in heterogeneous multiple myeloma. Clin Epigenetics (2017) 0.75
Selective Inhibitors of Histone Deacetylases 1 and 2 Synergize with Azacitidine in Acute Myeloid Leukemia. PLoS One (2017) 0.75
Effective use of panobinostat in combination with other active agents in myeloma in a novel five-drug combination: Case report and interesting observations. Am J Hematol (2016) 0.75
Carfilzomib boosted combination therapy for relapsed multiple myeloma. Onco Targets Ther (2017) 0.75
Three cases of relapsed/refractory multiple myeloma under hemodialysis treated with panobinostat/bortezomib/dexamethasone (FVD). Int J Hematol (2017) 0.75
A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas. Leuk Lymphoma (2017) 0.75
RECQ1 helicase is involved in replication stress survival and drug resistance in multiple myeloma. Leukemia (2017) 0.75
The potential of ixazomib, a second-generation proteasome inhibitor, in the treatment of multiple myeloma. Ther Adv Hematol (2017) 0.75
Emerging drugs and combinations to treat multiple myeloma. Oncotarget (2017) 0.75
Novel Proteasome Inhibitors and Histone Deacetylase Inhibitors: Progress in Myeloma Therapeutics. Pharmaceuticals (Basel) (2017) 0.75
Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy. Mayo Clin Proc (2017) 0.75
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol (2014) 4.37
Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. Lancet Oncol (2014) 2.05
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol (2016) 1.41
Panobinostat for the Treatment of Multiple Myeloma. Clin Cancer Res (2015) 0.91
Proteomic profiling of naïve multiple myeloma patient plasma cells identifies pathways associated with favourable response to bortezomib-based treatment regimens. Br J Haematol (2015) 0.81
Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial. Lancet Haematol (2016) 0.79
Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy. Haematologica (2014) 0.79
Phase 2 study of dovitinib in patients with relapsed or refractory multiple myeloma with or without t(4;14) translocation. Eur J Haematol (2015) 0.79
Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma. Br J Haematol (2017) 0.77
A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma. Br J Haematol (2017) 0.77
Panobinostat PK/PD profile in combination with bortezomib and dexamethasone in patients with relapsed and relapsed/refractory multiple myeloma. Eur J Clin Pharmacol (2015) 0.76
Cladribine added to daunorubicin-cytarabine induction prolongs survival of FLT3-ITD+ normal karyotype AML patients. Blood (2015) 0.76
Diagnostic pathways in multiple myeloma and their relationship to end organ damage: an analysis from the Tackling Early Morbidity and Mortality in Myeloma (TEAMM) trial. Br J Haematol (2020) 0.75
Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk. J Hematol Oncol (2020) 0.75
Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study. J Hematol Oncol (2017) 0.75
Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the PANORAMA 1 trial. Br J Haematol (2017) 0.75
Characteristics and outcomes of patients with multiple myeloma aged 21-40 years versus 41-60 years: a multi-institutional case-control study. Br J Haematol (2016) 0.75
Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study. J Clin Oncol (2021) 0.75
Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses. Target Oncol (2017) 0.75
IgM Myeloma: A Multicenter Retrospective Study of 134 Patients. Am J Hematol (2017) 0.75
Efficacy of rabbit antithymocyte globulin as first-line treatment of severe aplastic anemia: an Asian multicenter retrospective study. Int J Hematol (2016) 0.75
Impact of concomitant dexamethasone dosing schedule on bortezomib-induced peripheral neuropathy in multiple myeloma. Br J Haematol (2017) 0.75
Hematology oncology practice in the Asia-Pacific APHCON survey results from the 6th international hematologic malignancies conference: bridging the gap 2015, Beijing, China. Oncotarget (2017) 0.75
Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis. Eur J Haematol (2017) 0.75
Phase II study of bortezomib, cyclophosphamide and dexamethasone as induction therapy in multiple myeloma: DSMM XI trial. Br J Haematol (2017) 0.75
Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1. Haematologica (2017) 0.75
Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice. Am J Hematol (2016) 0.75